PUBLISHER: Grand View Research | PRODUCT CODE: 1587411
PUBLISHER: Grand View Research | PRODUCT CODE: 1587411
The global peripheral vascular devices market size is expected to reach USD 14.8 billion by 2030, registering a CAGR of 5.8% from 2025 to 2030, according to a new report by Grand View Research, Inc. The factors driving market growth are the growing prevalence of peripheral arterial disease (pad), increasing clinical trials & studies, technological advancements, and government initiatives. Pharmaceutical companies and medical device manufacturers are increasingly funding clinical trials to explore innovative solutions for peripheral vascular disease PVD. This trend accelerates product development cycles and encourages collaboration between industry stakeholders and academic institutions.
As more studies are initiated, the data generated can significantly help improve these devices' performance and effectiveness. Moreover, regulatory support for increasing clinical trials is anticipated to boost these initiatives, thereby enhancing the development of advanced solutions in the market. For instance, in June 2024, AVS received an Investigational Device Exemption (IDE) from the FDA to conduct a clinical trial for its Pulsatile Intravascular Lithotripsy (PIL) system. The trial will assess the safety and effectiveness of the PIL system in patients with peripheral artery disease. AVS plans to initiate the study across multiple sites, marking a significant step forward in developing less invasive treatment options for patients suffering from calcified vascular conditions. Such efforts by market players, coupled with the developing R&D environment, are expected to drive market growth over the forecast period.
Moreover, the evolving competitive landscape of the peripheral vascular devices market is leading to several initiatives by market players that significantly increase their offerings and availability of these advanced devices to the healthcare sector globally, such as partnerships, expansion, agreements, acquisitions, and others. For instance, in June 2024, Boston Scientific announced an agreement to acquire Silk Road Medical, Inc., specializing in innovative solutions for carotid artery disease. The acquisition, valued at approximately USD 1.1 billion, aims to enhance Boston Scientific's portfolio in vascular intervention and expand its presence in the growing carotid artery market. Such initiatives by the market players to increase their offers, coupled with the growing availability of these devices, are expected to drive market growth over the forecast period.